FLUOROPHARMA MEDICAL.........

FLUOROPHARMA MEDICAL INC Aktie ..buran und MfG  

Datum Erster Hoch Tief Schluss     Stücke Volumen
  06.11.13      0,60      0,60§0,54 0,54 $ 36.740 21.634

GrB  

engages in the discovery, development and commercialization of proprietary medical diagnostic imaging products. The company’s initial focus is the development of breakthrough positron emission tomography (PET) imaging agents for the efficient detection and assessment of acute and chronic forms of coronary artery disease (CAD). Other products in development include agents for detection of inflamed atherosclerotic plaque in peripheral arteries, amyloid plaque in Alzheimer’s disease and agents for detection of certain types of cancer.http://ir.stockpr.com/fluoropharma/overview  

FluoroPharma Medical, Inc. Names GE Healthcare Veteran, Edward L. Lyons, Jr. to Newly Created Position of Vice President, Marketing
Broad Healthcare Industry and Global Experience Will Advance FluoroPharma's Nuclear Cardiology Strategy and Strengthens Goal for Commercialization in 2016

MONTCLAIR, NJ -- (Marketwired) -- 10/28/13 -- FluoroPharma Medical, Inc. (OTCQB: FPMI), a company specializing in the development of novel diagnostic imaging products that utilize positron emission tomography (PET) technology for the detection and assessment of disease before clinical manifestation, announced today that Edward L. Lyons, GE Healthcare's Global Marketing Director, Nuclear Medicine, has been named to FluoroPharma's newly created position of Vice President, Marketing, effective today.

Mr. Lyons will be responsible for the global development and commercial strategy for FluoroPharma's nuclear cardiology portfolio and will report directly to FluoroPharma's Chairman and CEO, Thijs Spoor.

"We are delighted that Ed Lyons, a distinguished healthcare veteran with vast experience in nuclear cardiology across the health care continuum, from hospital to pharmaceuticals and diagnostics; and with the expertise to develop strategic and operational programs that drive growth, has joined our company at such a defining moment in our evolution. Today's announcement reflects the confidence we have in our vision to enable personalized medicine through precision diagnostics, the strength of our science and the promise of our portfolio. We created this position to manage our global strategies, advance our approach to launching, marketing and selling our products as well as strengthening our potential for strategic partnerships," said Mr. Spoor.

"I am excited to be a member of the FluoroPharma team and look forward to contributing to our success. My career has been devoted to diagnostic imaging, and PET is ideal for the early detection and diagnosis of diseases. I believe that the development of new molecular diagnostic imaging agents will extend the utility of PET, while helping to address the global economic challenges of healthcare delivery. FluoroPharma's diagnostics could provide better information for clinicians that will further enable doctors and patients to make more informed choices on treatment. I believe FluoroPharma's pipeline holds great promise, I am confident we have the tools to make the promise become the reality," said Mr. Lyons.

Prior to joining FluoroPharma, Mr. Lyons was with GE Healthcare where he held management positions of increasing responsibility, culminating in his appointment to Global Marketing Director, Nuclear Medicine, where he was responsible for the worldwide marketing of the general purpose, hybrid imaging and direct-conversion detector camera portfolios. During his tenure with GE Healthcare, Mr. Lyons successfully launched AdreView ™ and was responsible for the Cardiology commercial and development portfolios. In 2008, the business received the Frost and Sullivan Award for Radiopharmaceutical Marketing Excellence.

Before GE Healthcare, Mr. Lyons was with Bristol-Myers Squibb Medical Imaging, where he held positions in Medical Affairs Field Operations and Marketing. Prior to Bristol-Myers, Mr. Lyons was with DuPont Pharmaceuticals, where over the span of ten years he held positions in Nuclear Cardiology ranging from Sales and Marketing to Medical Affairs, where he was appointed to Director. Mr. Lyons began his career within the hospital environment, where he was Chief Technologist in Nuclear Medicine and Nuclear Cardiology at Philadelphia Heart Institute, and Temple University Hospital.

Throughout his career, Mr. Lyons has contributed to numerous publications and white papers, and has presented on a variety of medical imaging topics at prestigious industry conferences and meetings.

Mr. Lyons has a diverse educational background in Management Theory and Practice, Marketing Excellence, Strategic Planning and Six Sigma. He holds active board certifications from Temple University School of Nuclear Medicine Technology and Albert Einstein School of Radiologic Technology.

About FluoroPharma Medical

FluoroPharma is a biopharmaceutical company engaged in the discovery and development of proprietary PET imaging products to evaluate cardiac disease at the cellular and molecular levels. The Company has licensed technology from the Massachusetts General Hospital in Boston.

The Company's goal is to enable personalized medicine through precision diagnostics that will help the medical community diagnose disease more accurately at the earliest stages, leading to more effective treatment, management and better patient outcomes.

FluoroPharma's initial focus is the development of breakthrough positron emission tomography (PET) imaging agents and is advancing two products in clinical trials for assessment of acute and chronic forms of coronary artery disease. These first in class agents have been designed to rapidly target myocardial cells. Other products in development include agents for detection of inflamed atherosclerotic plaque in peripheral arteries, agents with the potential to image brain tissue affected by Alzheimer's disease and agents that could potentially be used for imaging specific cancers.

In addition to the United States, Europe and China, patents related to FluoroPharma's portfolio of imaging compounds have been issued in Japan, Canada, Australia, Finland, Portugal, Ireland and Mexico.

For more information on the Company, please visit: www.fluoropharma.com

Forward-Looking Statements

Except for historical information contained herein, the statements in this release are forward-looking. Forward-looking statements are inherently unreliable and actual results may differ materially. Examples of forward-looking statements in this news release include statements regarding FluoroPharma's research and development activities and anticipated operating results. Factors which could cause actual results to differ materially from these forward-looking statements include such factors as significant fluctuations in expenses associated with clinical trials, failure to secure additional financing, the inability to complete regulatory filings with the Food and Drug Administration, the introduction of competing products, or management's ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and other information that may be detailed from time to time in FluoroPharma's filings with the United States Securities and Exchange Commission. FluoroPharma undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACT:

Media:
Carol Perlman
FluoroPharma Medical, Inc.
cperlman@fluoropharma.com
Phone: 917-592-9260

Investor Relations:
Richard Moyer
Cameron Associates, Inc.
Richard@cameronassoc.com
Phone: 212-554-5466

Source: FluoroPharma Medical, Inc.

Released October 28, 2013
http://ir.stockpr.com/fluoropharma/company-news/...resident-marketing  

CONSOLIDATED BALANCE SHEETS (USD $)
                    §
Jun. 30, 2013
                    §
Dec. 31, 2012
Current Assets:
Cash and cash equivalents $ 65,935 $ 1,304,088
Prepaid expenses & other 30,711 77,310
Total Current Assets 96,646 1,381,398
Property and equipment, net 168,709 176,889
Intangible assets, net 52,293 55,247
Total Assets 317,648 1,613,534
Current Liabilities:
Accounts payable 339,827 137,779
Notes Payable - Stockholders 200,000  
Accrued expenses 34,134 97,728
Total Current Liabilities 573,961 235,507
Stockholders' Equity (Deficit):
Preferred stock Series A - $0.001 par value, 3,500,000 designated 2,234,673 and 2,126,574 shares issued and outstanding at June 30, 2013 and at December 31, 2012, respectively (preference in liquidation of $1,854,779 at June 30, 2013) 2,236 2,127
Common stock - Class A - $0.001 par value, 200,000,000 shares authorized, 24,375,013 and 24,330,013 shares issued and outstanding at June 30, 2013 and December 31, 2012, respectively 24,376 24,331
Additional paid-in capital 18,786,302 18,242,109
Deficit accumulated in the development stage (19,069,227) (16,890,540)
Total Stockholders' Equity (Deficit) (256,313) 1,378,027
Total Liabilities and Stockholders' Equity (Deficit) $ 317,648 $ 1,613,534
http://ir.stockpr.com/fluoropharma/financials  

3:57 PM EST Nov 6, 2013

Last Price
0.54
                    §
Change $
0.06
                    §
Change %
10.00%
          
Tick
N/A
Bid
N/A
           §
Bid Size
0
          
Ask
N/A
           §
Ask Size
0
Open
0.60
          
High
0.60
           
Low
0.54
           §
Prev Close
0.60
Last Trade
3:57
          
Volume
36.74k
           §
52 Wk Hi
0.95
                    §
52 Wk Low
0.51
Market Cap
13.17m
                    §
Ex-Div Date
N/A
                    §
Div Rate
N/A
          
Yield
N/A
Shares
24,380,013
           §
EPS (TTM)
-0.15
                    §
PE Ratio
N/A
          
Exchange
OTCBB§
http://ir.stockpr.com/fluoropharma/quote  

http://ir.stockpr.com/fluoropharma/all-sec-filings GrB  

Zeit   Kurs Stück
  21:34:05§0,56 $ 2.500
_____________________
GRATULATION  

::::::::::::::: 0,56 $ +3,70% +0,02 $ In Euro: 0,4177 € | Nasdaq OTC BB, 07.11.13 ,GrB  

Zeit   Kurs Stück
  15:51:28§0,55 $ 4.000
_____________________
GRATULATION  

Zeit    Kurs Stück
  15:30:26§0,53 $ 1.000

..Glückwunsch  

Zeit
                Kurs               Stück                    §
  18:34:31§0,52 $
              20.000                    §
  18:12:32§0,52 $
              20.000                    §
  17:36:06§0,52 $
              20.000                    §
  16:01:22§0,50 $
              50.000                    §
  16:01:16§0,50 $
          50.000
§
Kosmonova buran  

Zeit
                Kurs               Stück                    §
  17:47:46§0,51 $
                 225                    §
  17:02:53§0,50 $
               8.487                    §
  16:28:40§0,51 $
               1.000                    §
  16:28:10§0,51 $
               4.000                    §
  16:17:18§0,50 $
              20.600                    §
  16:12:41§0,51 $
           1.000
§
buran und THX und weitermachen  

Zeit
                Kurs               Stück                    §
  17:45:54§0,52 $
              19.500                    §
  15:37:30§0,58 $
               1.000                    §
  15:35:10§0,58 $
               1.000                    §
  15:34:42§0,58 $
           3.400
§
buran und MfG  

Datum Erster Hoch Tief Schluss     Stücke Volumen
  18.11.13      0,57      0,57§0,57 0,57 $ 3.300 1.881

GrB  

Datum Erster Hoch Tief Schluss     Stücke Volumen
20.11.13 0,57 0,57 0,57   0,57 $ 700 399

GrB  

::::::::::::: 0,575 $ +0,88% +0,005 $
In Euro: 0,4242 € | Nasdaq OTC BB, 22.11.13 ,GrB  

Zeit


      Kurs               Stück                    §
  21:42:38§0,575 $
     1.000                    §
  20:50:18§0,56 $
     1.000                    §
  20:49:21§0,56 $
     9.000                    §
  19:27:00§0,58 $
       700                    §
  16:30:13§0,58 $
100
_____________
GRATULATION  

Datum Erster Hoch Tief Schluss     Stücke Volumen
  25.11.13      0,58      0,58§0,56 0,575 $ 11.800 6.639

GrB  

Zeit


      Kurs               Stück                    §
  19:07:12§0,58 $
    10.000                    §
  18:11:03§0,60 $
     1.600                    §
  17:45:11§0,60 $
     2.800                    §
  17:45:08§0,58 $
     2.200                    §
  16:59:43§0,58 $
     1.765                    §
  15:36:10§0,575 $
9.235

Kosmonova buran und MfG und danke und weitermachen  

::::::::::::::::: 0,58 $ +0,87% +0,005 $
In Euro: 0,4266 € | Nasdaq OTC BB, 26.11.13 ,GrB  

0.58 0.01(0.87%) Nov 26, 2:39PM EST|Pre-Market : NaN

Prev Close: 0.57
     Open:0.57
      Bid: N/A
      Ask: N/A§
1y Target Est: 1.20
     Beta:     -0.01§
Next Earnings Date: N/A
Day's Range: 0.57 - 0.60
52wk Range: 0.48 - 0.95
   Volume:    31,509§
Avg Vol (3m): 26,012
Market Cap: 14.15M
P/E (ttm): N/A
EPS (ttm): -0.25
Div & Yield: N/A (N/A)
http://finance.yahoo.com/q?s=fpmi&ql=1  

29-Oct-2013

Other Events, Financial Statements and Exhibits


Item 8.01. Other Events.
On October 28, 2013, FluoroPharma Medical, Inc. (the "Company") announced that Edward L. Lyons, GE Healthcare's Global Marketing Director, Nuclear Medicine, has been named to the Company's newly created position of Vice President, Marketing, effective as of October 28, 2013.

The press release relating to the foregoing is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.



Item 9.01. Financial Statement and Exhibits.
(d) Exhibits.

Exhibit No. Description

99.1 Press Release dated October 28, 2013.
http://biz.yahoo.com/e/131029/fpmi8-k.html  

14-Nov-2013

Quarterly Report


Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations
This report contains forward-looking statements. These forward-looking statements include, without limitation, statements containing the words "believes","anticipates","expects","intends","projects","will" and other words of similar import or the negative of those terms or expressions. Forward-looking statements in this report include, but are not limited to, expectations of future levels of research and development spending, general and administrative spending, levels of capital expenditures and operating results, sufficiency of our capital resources, our intention to pursue and consummate strategic opportunities available to us.. Forward-looking statements are subject to certain known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to those described in "Risk Factors" of the reports we file with the SEC.

Overview

We are a biopharmaceutical company specializing in discovering, developing and commercializing molecular imaging pharmaceuticals with initial applications in the area of cardiology. Molecular imaging pharmaceuticals are radiopharmaceuticals that enable early detection of disease through the visualization of subtle changes in biochemical and biological processes. We currently have two clinical-stage molecular imaging pharmaceutical product candidates: CardioPET and BFPET. Additionally we have identified potential candidates that may be useful in the detection and/or treatment of vulnerable plaque.
http://biz.yahoo.com/e/131114/fpmi10-q.html  

By Brian Marckx, CFA

Q3 2013 10-Q Filed

FluoroPharma (OTC BB:FPMI) filed their 10-Q for the third quarter ending September 30, 2013.  Aside from operating expenses continuing to come in beneficially lower than our numbers, results remain mostly in-line with our estimates.  Cash burn also remains within our expectations.

Q3 operating expenses were $900k, about $200k lower than Q2 and about one-half as much as our $1.8 million estimate.  We continue to expect operating expenses to increase with clinical trials progression.  Q3 net loss to common and EPS were $2.5 million and ($0.10) but excluding $1.35 million accounted for as non-cash preferred dividends ("deemed dividend") related to revaluation of the conversion feature of the recently issued Series B preferred stock, net loss to common and EPS were $1.2 million and ($0.05), compared to our $1.9 million loss and ($0.07) estimates.

Cash used in operating activities was $564k in Q3, down from $765k in Q2.  Cash burn is averaging about $670k/quarter in 2013, down from about $825k/quarter in 2012.
http://finance.yahoo.com/news/...ndustry-veteran-hired-130000423.html